RET and non-small cell lung carcinoma: Thus, the results from pralsetinib and selpercatinib trials showed that these RET-specific TKIs gave high response rates comparable to those of ALK- and ROS1 fusion-targeted therapies in NSCLC at the tolerated doses and the responses were more durable than that of the multi-targeted TKIs with RET inhibitor activity.